Table 1.
Clinical characteristics of advanced pancreatic cancer patients.
| Characteristics | N (%) (n = 132) |
|---|---|
| Gender | |
| Male | 85 (64.4) |
| Female | 47 (35.6) |
| Age | |
| >60 | 41 (31.1) |
| ≤60 | 91 (68.9) |
| KPS | |
| 90 | 108 (81.8) |
| 80 | 20 (15.2) |
| 70 | 4 (3) |
| Location | |
| Head | 46 (34.8) |
| Body/tail | 86 (65.2) |
| Stage at diagnosis | |
| Locally advanced | 31 (23.5) |
| Distant metastasis | 101 (76.5) |
| Albumin (g/L) | |
| ≤35 | 11 (8.3) |
| >35 | 121 (91.7) |
| Baseline WBC (×10 9 /L) | |
| median (range) | 6.515 (4.39–11.88) |
| Baseline Hemoglobin (g/L) | |
| median (range) | 129 (101.65–156.35) |
| Baseline Platelets (×10 9 /L) | |
| median (range) | 191.5 (106–311.5) |
| WBC after 2 cycles (×10 9 /L) | |
| median (range) | 5.625 (2.78–13.68) |
| Hemoglobin after 2 cycles (g/l) | |
| median (range) | 111 (87.65–135.4) |
| Platelets after 2 cycles (×10 9 /L) | |
| median (range) | 198 (83.7–404.2) |
| Baseline NLR | |
| ≤2.78 | 54 (40.9) |
| >2.78 | 78 (59.1) |
| ΔNLR | |
| ≤0 | 82 (62.1) |
| >0 | 50 (37.9) |
| Chemotherapy regimens | |
| gemcitabine monotherapy | 42 (31.8) |
| Gemcitabine and S1/capecitabine | 15 (11.4) |
| Gemcitabine and nab-Paclitaxel | 13 (9.8) |
| Gemcitabine and cisplatin/oxaliplatin | 6 (4.5) |
| nab-Paclitaxel and S1 | 56 (42.5) |
Abbreviations: KPS: Karnofsky Performance Status; WBC: White blood cell count; NLR: neutrophil to lymphocyte ratio; ΔNLR: ΔNLR was calculated by subtracting the baseline NLR from the NLR after 2 cycles of chemotherapy (cycle 2-cycle 0).